People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

18 Oct 2019
Change (% chg)

$0.25 (+0.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Repella, Robert 

Mr. Robert Repella RPh., MBA., is Director of the Company. Mr. Repella has served as a director of our Company since September 2018. Mr. Repella served as Chief Executive Officer and as a member of the Board of Directors of Harmony Biosciences, LLC, a private biotechnology company, from October 2017 through July 2018. Prior to this, he served as the Executive Vice President, Global Commercial Operations for CSL Behring, Inc., a biotherapeutics company, from March 2014 to September 2017, as Senior Vice President and Chief Commercial Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) from October 2011 to January 2014 and as Senior Vice President Pharmaceutical Operations, Americas Region of Cephalon Inc. from October 2009 to October 2011. Mr. Repella has over twenty years of leadership experience in the biotech and pharmaceutical industries, with past experience at Wyeth Pharmaceuticals, Johnson & Johnson, Merck & Company, and Eli Lilly & Company. Mr. Repella has also served on the Board of Directors of the Biotechnology Industry Association (BIO), Pennsylvania BIO and the New York chapter of the Arthritis Foundation. Mr. Repella obtained a Masters of Business Administration from Temple University and earned his Bachelor of Science degree in Pharmacy from Rutgers University. We believe that Mr. Repella’s background and experience as an investor in life science companies qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD 1,242,720
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 16,625
Fiscal Year Total, USD 1,259,340

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan


Vlad Coric


James Engelhart


Kimberly Gentile


Charles Conway


Robert Berman

As Of  31 Dec 2018